BACKGROUND: New chemotherapeutic agents, including paclitaxel and gemcitabine, are active in advanced bladder carcinoma, and combination regimens with these agents have shown promising results. Unlike conventional chemotherapy regimens, such as methotrexate, vinblastine, doxorubicin, and cisplatin, there are no data available on key predictive factors for response and survival with these novel agents. Since this information is needed for selection of patients for these new combinations and for stratification purposes in ongoing randomized trials, the authors aimed to study the predictive factors for response and survival to the current regimen containing cisplatin, paclitaxel, and gemcitabine. METHODS: The authors studied 56 patients with advanced urothelial tumors treated on a Phase I/II trial of paclitaxel, cisplatin, and gemcitabine (TCG) to identify pretreatment characteristics that were prognostic for survival using this novel combination. The pretreatment characteristics analyzed were age, gender, Eastern Cooperative Oncology Group performance status, histopathology (pure transitional versus other), visceral (liver, lung, or bone) metastasis, number of sites of disease, lactate dehydrogenase, and hemoglobin. RESULTS: The factors that were associated with a worse survival in univariate analysis were performance status > 0, presence of visceral metastasis, and more than one site of malignant disease. In a multivariate model, performance status (P = 0.044) and visceral disease (P = 0.008) showed independent statistical significance for decreased survival. Patients were then grouped based on these two independent prognostic factors. Median survival times in the groups of patients with zero, one, or two of these risk factors were 32.8 months, 17 months, and 9.6 months, respectively (P = 0.0005). CONCLUSIONS: A pretreatment performance status > 0 and the presence of visceral metastasis have a profound impact on survival when using the TCG regimen. These two variables will be used to stratify patients in the upcoming Phase III randomized trial comparing this TGC regimen with a gemcitabine/cisplatin regimen in advanced urothelial tumors. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10762
BACKGROUND: New chemotherapeutic agents, including paclitaxel and gemcitabine, are active in advanced bladder carcinoma, and combination regimens with these agents have shown promising results. Unlike conventional chemotherapy regimens, such as methotrexate, vinblastine, doxorubicin, and cisplatin, there are no data available on key predictive factors for response and survival with these novel agents. Since this information is needed for selection of patients for these new combinations and for stratification purposes in ongoing randomized trials, the authors aimed to study the predictive factors for response and survival to the current regimen containing cisplatin, paclitaxel, and gemcitabine. METHODS: The authors studied 56 patients with advanced urothelial tumors treated on a Phase I/II trial of paclitaxel, cisplatin, and gemcitabine (TCG) to identify pretreatment characteristics that were prognostic for survival using this novel combination. The pretreatment characteristics analyzed were age, gender, Eastern Cooperative Oncology Group performance status, histopathology (pure transitional versus other), visceral (liver, lung, or bone) metastasis, number of sites of disease, lactate dehydrogenase, and hemoglobin. RESULTS: The factors that were associated with a worse survival in univariate analysis were performance status > 0, presence of visceral metastasis, and more than one site of malignant disease. In a multivariate model, performance status (P = 0.044) and visceral disease (P = 0.008) showed independent statistical significance for decreased survival. Patients were then grouped based on these two independent prognostic factors. Median survival times in the groups of patients with zero, one, or two of these risk factors were 32.8 months, 17 months, and 9.6 months, respectively (P = 0.0005). CONCLUSIONS: A pretreatment performance status > 0 and the presence of visceral metastasis have a profound impact on survival when using the TCG regimen. These two variables will be used to stratify patients in the upcoming Phase III randomized trial comparing this TGC regimen with a gemcitabine/cisplatin regimen in advanced urothelial tumors. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10762
Authors: Lauren C Harshman; Gerold Bepler; Zhong Zheng; John P Higgins; Genevera I Allen; Sandy Srinivas Journal: BJU Int Date: 2010-12 Impact factor: 5.588
Authors: Pedro C Barata; Dhrmesh Gopalakrishnan; Vadim S Koshkin; Prateek Mendiratta; Matt Karafa; Kimberly Allman; Allison Martin; Jennifer Beach; Pam Profusek; Allison Tyler; Laura Wood; Moshe Ornstein; Timothy Gilligan; Brian I Rini; Jorge A Garcia; Petros Grivas Journal: Target Oncol Date: 2018-06 Impact factor: 4.493
Authors: Andrea B Apolo; Irina Ostrovnaya; Susan Halabi; Alexia Iasonos; George K Philips; Jonathan E Rosenberg; Jamie Riches; Eric J Small; Matthew I Milowsky; Dean F Bajorin Journal: J Natl Cancer Inst Date: 2013-02-14 Impact factor: 13.506
Authors: Joaquim Bellmunt; Hans von der Maase; Graham M Mead; Iwona Skoneczna; Maria De Santis; Gedske Daugaard; Andreas Boehle; Christine Chevreau; Luis Paz-Ares; Leslie R Laufman; Eric Winquist; Derek Raghavan; Sandrine Marreaud; Sandra Collette; Richard Sylvester; Ronald de Wit Journal: J Clin Oncol Date: 2012-02-27 Impact factor: 44.544
Authors: Alexandra Masson-Lecomte; Evanguelos Xylinas; Morgane Bouquot; Mathilde Sibony; Yves Allory; Eva Comperat; Marc Zerbib; Alexandre de la Taille; Morgan Rouprêt Journal: World J Urol Date: 2014-09-02 Impact factor: 4.226
Authors: Stephanie A Mullane; Lillian Werner; Elizabeth A Guancial; Rosina T Lis; Edward C Stack; Massimo Loda; Philip W Kantoff; Toni K Choueiri; Jonathan Rosenberg; Joaquim Bellmunt Journal: Clin Genitourin Cancer Date: 2015-12-24 Impact factor: 2.872